Open Nav

Please submit your session questions in advance at

Trovagene Oncology

  • Thomas Adams, Trovagene Oncology

Trovagene is a clinical-stage oncology therapeutics company, developing drugs that target mitosis (cell division) and integrating a biomarker approach to identifying patient most likely to respond to treatment. Currently, 3 clinical trials are underway with lead drug candidate, Onvansertib, a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1(PLK1) inhibitor: a Phase 1b/2 trial of Onvansertib in combination with standard-of-care chemo in Acute Myeloid Leukemia (AML); a Phase 2 trial of Onvansertib in combination with Zytiga in metastatic Castration-Resistant Prostate Cancer (mCRPC; and a Phase 1b/2 trial of Onvansertib in combination with FOLFIRI and Avastin in metastatic Colorectal Cancer (mCRC).

  • Date:Monday, February 11
  • Time:3:30 PM - 3:45 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23544
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Introducing the Company and providing updates around key milestones anticipated in 2019
  • Company
  • Company HQ City:San Diego
  • Company HQ State:California
  • Company HQ Country:United States
  • Ticker:TROV
  • Exchange:Nasdaq
  • CEO/Top Company Official:Dr. Thomas Adams - CEO and Chairman
  • Year Founded:2009
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:Onvansertib
  • Development Phase of Primary Product:Phase II
Thomas Adams
Trovagene Oncology